NPY modulates PYY function in the regulation of energy balance and glucose homeostasis

Diabetes, Obesity and Metabolism

Volumn 14, Issue 8, 2012, Pages 727-736

  Zhang, L ^a   Nguyen, A D ^a   Lee, I C J ^a   Yulyaningsih, E ^a   Riepler, S J ^a   Stehrer, B ^a   Enriquez, R F ^a   Lin, S ^a   Shi, Y C ^a   Baldock, P A ^a,b   Sainsbury, A ^a,b,c   Herzog, H ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Energy regulation; Glucose metabolism; Insulin secretion

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCOSE; INSULIN; NEUROPEPTIDE Y; PEPTIDE YY;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL HORMONE DISORDER; GLUCOSE HOMEOSTASIS; HYPERPHAGIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN TOLERANCE TEST; LUNG GAS EXCHANGE; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PEPTIDE YY DEFICIENCY; PHYSICAL ACTIVITY;

EID: 84863312734     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01592.x     Document Type: Article

References (49)

1. Zhang L, Bijker M, Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 2011; 23: 23.
2. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 1984; 8: 225-235.
3. Bai FL, Yamano M, Shiotani Y et al. An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Res 1985; 331: 172-175.
4. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
5. Unniappan S, McIntosh CH, Demuth HU, Heiser U, Wolf R, Kieffer TJ. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 2006; 49: 1915-1923.
6. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 2002; 23: 251-261.
7. Adrian TE, Sagor GR, Savage AP, Bacarese-Hamilton AJ, Hall GM, Bloom SR. Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. J Clin Endocrinol Metab 1986; 63: 803-807.
8. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
9. Acosta A, Hurtado MD, Gorbatyuk O et al. Salivary PYY: a putative bypass to satiety. PLoS One 2011; 6: e26137.
10. Blomqvist AG, Herzog H. Y-receptor subtypes-how many more? Trends Neurosci 1997; 20: 294-298.
11. Michel MC, Beck-Sickinger A, Cox H et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998; 50: 143-150.
12. Yulyaningsih E, Zhang L, Herzog H, Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 2011; 24: 1476-5381.
13. Shi YC, Lin S, Castillo L et al. Peripheral-specific Y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity (Silver Spring) 2011; 5: 5.
14. Zhang L, Macia L, Turner N et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes (Lond) 2010; 34: 357-373.
15. Wisialowski T, Parker R, Preston E et al. Adrenalectomy reduces neuropeptide Y-induced insulin release and NPY receptor expression in the rat ventromedial hypothalamus. J Clin Invest 2000; 105: 1253-1259.
16. Jackerott M, Larsson LI. Immunocytochemical localization of the NPY/PYY Y1 receptor in the developing pancreas. Endocrinology 1997; 138: 5013-5018.
17. Sheikh SP, Roach E, Fuhlendorff J, Williams JA. Localization of Y1 receptors for NPY and PYY on vascular smooth muscle cells in rat pancreas. Am J Physiol 1991; 260(2 Pt 1): G250-257.
18. Morgan DG, Kulkarni RN, Hurley JD et al. Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 1998; 41: 1482-1491.
19. Sindelar DK, Mystkowski P, Marsh DJ, Palmiter RD, Schwartz MW. Attenuation of diabetic hyperphagia in neuropeptide Y-deficient mice. Diabetes 2002; 51: 778-783.
20. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415-421.
21. Segal-Lieberman G, Trombly DJ, Juthani V, Wang X, Maratos-Flier E. NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. Am J Physiol Endocrinol Metab 2003; 284: E1131-1139.
22. Patel HR, Qi Y, Hawkins EJ et al. Neuropeptide Y deficiency attenuates responses to fasting and high-fat diet in obesity-prone mice. Diabetes 2006; 55: 3091-3098.
23. Boey D, Lin S, Karl T et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49: 1360-1370.
24. Batterham RL, Heffron H, Kapoor S et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4: 223-233.
25. Karl T, Duffy L, Herzog H. Behavioural profile of a new mouse model for NPY deficiency. Eur J Neurosci 2008; 28: 173-180.
26. Doyle KL, Karl T, Hort Y, Duffy L, Shine J, Herzog H. Y1 receptors are critical for the proliferation of adult mouse precursor cells in the olfactory neuroepithelium. J Neurochem 2008; 105: 641-652.
27. Zhang L, Lee NJ, Nguyen AD et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010; 12: 591-603.
28. Cox HM, Tough IR, Woolston AM et al. Peptide YY Is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010; 11: 532-542.
29. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988; 37: 287-301.
30. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634.
31. McLean JA, Tobin G. Animal and Human Calorimetry. New York: Cambridge University Press, 1987.
32. Bannon AW, Seda J, Carmouche M et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 2000; 868: 79-87.
33. Sainsbury A, Zhang L. Role of the arcuate nucleus of the hypothalamus in regulation of body weight during energy deficit. Mol Cell Endocrinol 2010; 316: 109-119.
34. Acuna-Goycolea C, van den Pol AN. Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 2005; 25: 10510-10519.
35. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007; 293: E604-609.
36. Adams SH, Lei C, Jodka CM et al. PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J Nutr 2006; 136: 195-201.
37. Sloth B, Holst JJ, Flint A, Gregersen NT. Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 2007; 292: E1062-1068.
38. van den Hoek AM, Heijboer AC, Voshol PJ et al. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 2007; 292: E238-245.
39. Bottcher G, Ahren B, Lundquist I, Sundler F. Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 1989; 4: 282-288.
40. Ahren B, Larsson H. Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. Eur J Endocrinol 1996; 134: 362-365.
41. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994; 43: 764-769.
42. Sainsbury A, Cusin I, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue. Diabetologia 1996; 39: 353-356.
43. Sainsbury A, Rohner-Jeanrenaud F, Cusin I et al. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-1277.
44. Vettor R, Pagano C, Granzotto M et al. Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats. Diabetologia 1998; 41: 1361-1367.
45. Greeley GH Jr., Lluis F, Gomez G, Ishizuka J, Holland B, Thompson JC. Peptide YY antagonizes beta-adrenergic-stimulated release of insulin in dogs. Am J Physiol 1988; 254(4 Pt 1): E513-517.
46. Guo YS, Singh P, DeBouno JF, Thompson JC. Effect of peptide YY on insulin release stimulated by 2-deoxyglucose and neuropeptides in dogs. Pancreas 1988; 3: 128-134.
47. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 2008; 295: E1323-1332.
48. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291: R367-375.
49. van den Hoek AM, Heijboer AC, Corssmit EP et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 2004; 53: 1949-1952.